RVMD - Revolution Medicines GAAP EPS of -$0.72 beats by $0.10 revenue of $7.01M beats by $4.07M
2023-05-08 16:18:46 ET
- Revolution Medicines press release ( NASDAQ: RVMD ): Q1 GAAP EPS of -$0.72 beats by $0.10 .
- Revenue of $7.01M (-7.5% Y/Y) beats by $4.07M .
- Financial Guidance
- Revolution Medicines is updating its financial guidance and now expects full year 2023 GAAP net loss to be between $360 and $400 million, which includes estimated non-cash stock-based compensation expense of $40 million and $50 million. The increase in expected 2023 GAAP net loss is a result of increased investments to support and strengthen clinical advancement of our first wave of RAS( ON ) Inhibitors, including expanding clinical supply and strengthening senior leadership across late-stage development, manufacturing, and commercial planning for RMC-6236.
For further details see:
Revolution Medicines GAAP EPS of -$0.72 beats by $0.10, revenue of $7.01M beats by $4.07M